MRI Contrast Media Agents Market Size, Growth, Trends | Report 2022-2030
Market Synopsis
MRI contrast media agents are widely used to identify the presence of tumors, aneurysms, and other abnormalities in the tissues. In 1981, the first MRI contrast agent, ferric chloride was used to identify abnormalities in the GI tract. Later gadolinium compound was identified and is said to be the gold standard of MRI contrast media. Newer agents are constantly being identified and investigated. The extremely stringent guideline is laid for the clinical use of such agents, which makes their use perilous. Each contrast agent follows a unique route of administration, right from the intravenous route to oral administration. They are categorized based on their chemical composition, magnetic properties, safety, efficacy, pharmacokinetics and pharmacodynamics, and their imaging property. This market holds a high growth potential due to the enormous research and development in this space to develop contrast media agents with reduced ill effects, minimized occurrence of adverse reactions, minimal dosing, and improved imaging efficacy.
Market Influencer
MRI scans are growing at a quicker rate across the globe and so is the use of these contrast media agents. Studies suggest that ~50-ton gadolinium contrast agents are used annually across the globe, creating a market space of ~1 billion dollars. The use of this agent is related to its unparallel advantages of increased vascular permeability, negligible waiting time before scans, high shelf stability, higher throughput, and high sensitivity to motion artifacts. Manganese-based contrast agents is also a type of paramagnetic agent, which is been highly researched in current times. On the other hand, superparamagnetic agents include iron-containing contrast agents such as ferumoxides, ferumoxtran, and ferumoxsil among others.
These agents have the dynamics to identify the progressions of brain tumor, liver cancer, or breast cancer and establish improved guidance during surgical intervention. Contrast media Enhanced MRI procedures are likely to increase in the future as the application of MRI expands and is made available to most patients across the globe and as the information obtained from a single contrast injection. However, variation in practice by end users, calls for greater standardization of protocols and utilization of the latest diagnostic algorithms.
The key players operating in the MRI contrast media agents market include Bayer AG, GE Healthcare LLC, Guerbet GmbH, Bracco Imaging Spa, Miltenyi Biotec B.V. & Co. Kg, Amag Pharmaceuticals among others.
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on MRI Contrast Media Agents Market
5.1. COVID-19 Landscape: MRI Contrast Media Agents Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global MRI Contrast Media Agents Market, By Product Type
8.1. MRI Contrast Media Agents Market, by Product Type, 2022-2030
8.1.1 Paramagnetic Agents
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Superparamagnetic Agents
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global MRI Contrast Media Agents Market, By Application
9.1. MRI Contrast Media Agents Market, by Application, 2022-2030
9.1.1. Gastrointestinal
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Intravenous
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hepatobiliary
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Reticuloendothelial
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global MRI Contrast Media Agents Market, By End-use
10.1. MRI Contrast Media Agents Market, by End-use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostic Imaging Center
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global MRI Contrast Media Agents Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GE Healthcare LLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Guerbet GmbH
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bracco Imaging Spa
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Miltenyi Biotec B.V. & Co. Kg
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amag Pharmaceuticals
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers